AMTX exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile operational foundation. The absence of an Altman Z-Score and negative profitability metrics—especially a -38.96% profit margin and -8.96% ROA—signal severe operational distress. Despite a 14.2% YoY revenue growth and recent positive EPS surprises, the company remains unprofitable with negative cash flow and extreme liquidity issues (current ratio of 0.07). The stock trades at a price/sales of 0.77, but this is misleading given the lack of sustainable earnings and deteriorating balance sheet. The 52-week price range of $1.22–$3.66 reflects high volatility and speculative risk.